Valuation
- Market cap
- 1,453,794,000
- Revenue TTM
- $234,600,000
- Net income TTM
- $-13,230,000
- PE ratio
- 335.07
- Forward PE
- —
- Profit margin
- -5.64%
- Debt to equity
- 0.00
Trading
- Volume
- 441,100
- Avg volume
- 489,634
- Day's range
- $48.28 – $49.83
- Shares out
- 29,895,000
- Stochastic %K
- 5%
- Beta
- 0.76
- Analysts
- Strong Sell
- Price target
- $84.90
Company profile
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular...
Show more
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 362 6295
- Website
- https://www.anaptysbio.com
- Address
- 10770 Wateridge Circle, Suite 210, San Diego, United States
Latest news
No headlines yet.
